The Interdisciplinary Autoimmune Summit (IAS) 2020 will take place July 10 through 12 in a virtual format. Attendees can expect to hear about all types of autoimmune disease from experts in gastroenterology, rheumatology, and dermatology.
IAS 2020 senior advisor Stephen B. Hanauer, MD, who is professor of medicine at Northwestern University Feinberg School of Medicine and medical director of the Digestive Health Center at Northwestern Medicine in Chicago, Illinois, will be presenting 2 sessions about treating inflammatory bowel disease (IBD).
Below are his answers to our most pressing questions about his upcoming session and IAS 2020.
AUTOIMMUNE LEARNING NETWORK: Can you give us a preview of your upcoming session at IAS 2020? What can attendees expect?
Stephen Hanauer: I will be presenting an update on how therapy for IBD is undergoing changes based on comparative effectiveness studies, real-world data, treating to target approaches, and the novel agents being developed for IBD therapy. I will provide perspective on how therapeutic decisions can be made based on both evidence and shared decision-making with patients.
ALN: How is presenting at a virtual conference different than presenting at an in-person conference?
SH: Over the past several months we have been increasingly accustomed to presenting educational material in virtual settings at every level of teaching—from medical students, house officers, and fellows to grand-round settings. While in-person presentations certainly expand the social interactions, I have found that virtual presentations can be very informative when they are well-presented and allow attendees to focus more directly on both the speaker and presentation.
ALN: Which sessions are you excited about attending?
SH: I am most excited to hear the interdisciplinary approaches and how they differ between immune mediated inflammatory diseases. The expert presenters provide interactive discussions regarding how we can approach management of complex inflammatory conditions.